- This event has passed.
June Webinar – Nanoparticle Biosafety
16 June, 2016 @ 12:00 pm - 1:00 pm CDTFree – $10.00
MABioN is proud to offer a webinar discussing the Nanomaterials Research and Safety.
The webinar will provide the attendee with an overview of nanomaterial research areas, while highlighting Dr. Achilefu’s own research and some discussion of safety procedures and potential issues that need to be considered when assessing the risk of nanomaterial research.
The presenter is Sam Achilefu, PhD. He is the Michel M. Ter-Pogossian Professor of Radiology, with
appointments in Biochemistry & Molecular Biophysics and Biomedical Engineering. Dr.
Achilefu earned his doctorate in molecular and materials chemistry as a French Government
Scholar at the University of Nancy, France in 1991. He completed his postdoctoral training
in molecular oxygen transport/hematology at Oxford University, UK, before joining the
Discovery Research Department of Mallinckrodt Medical in 1993. As Principal Scientist, Dr.
Achilefu led the liquid ventilation project for treating infant respiratory distress syndrome
and received additional training in medical imaging and methods. He left industry for an
academic career at Washington University School of Medicine in 2001 and rapidly rose
through the ranks, receiving tenure in 2005 and full professorship the next year. He serves
as the Chief of Optical Radiology, Director of Washington University Molecular Imaging
Center, Director of the Center for Multiple Myeloma Nanotherapy, Co-Leader of the
Oncologic Imaging Program of the Siteman Cancer Center, and Vice Chair for Innovation and
Entrepreneurship at Mallinckrodt Institute of Radiology.
His research interests are in the development of molecular imaging probes and therapeutic
molecules, new methods, and devices for imaging and treatment of cancer and other
biological applications. Among many innovations, Dr. Achilefu pioneered the development
and use of small peptide-near infrared fluorescent dye conjugates for molecular optical
imaging, an emerging technology that promises a new paradigm in disease diagnosis and
therapy. This seminal discovery is now used routinely for detecting cancer and monitoring
the efficacy of drugs, with clinical translation in progress at various institutions worldwide.
Other notable discoveries and inventions include a “universal” cancer-targeting drug for
selective detection and treatment of tumors, a wearable goggle device for guiding surgical
procedures, and an approach to selectively kill cancer without harming healthy tissues.